vincristine sulfate liposome injection + rituximab

Vincristine sulfate liposome injection is a formulation of the microtubule-targeting agent vincristine encapsulated in sphingomyelin/cholesterol-based liposomes, designed to optimize pharmacokinetics and improve tumor drug exposure by providing prolonged circulation and sustained release. It is FDA approved for adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in second or greater relapse or whose disease has progressed after two or more antileukemia therapies. Rituximab is a monoclonal antibody targeting CD20 on B cells, used primarily for B-cell malignancies. The combination of vincristine sulfate liposome injection and rituximab has been studied in relapsed/refractory diffuse large B-cell lymphoma, mantle cell lymphoma, and indolent B-cell lymphomas[1][2][5]. Vincristine acts by inhibiting microtubule formation during mitosis, leading to cell cycle arrest and apoptosis[6]. Rituximab induces cell death through complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and direct apoptosis via CD20 binding.

Brand names

Marqibo (for vincristine sulfate liposome injection)Rituxan (for rituximab)

Other names

Vincristine liposomal injectionVincristine sulfate liposomal injectionVCR (for vincristine, not specific to the liposomal form)